Quick Answer
Metagenomi Therapeutics, Inc. reported R&D Expense of $94.43 million for fiscal year 2025.
Metagenomi Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $94.43M | -13.5% |
| 2024 | $109.18M | +15.7% |
| 2023 | $94.40M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.28M | -3.7% | +12.3% |
| June 30, 2025 | $22.51M | -20.5% | -10.5% |
| March 31, 2025 | $25.14M | -20.0% | -4.2% |
| September 30, 2024 | $26.26M | -2.2% | -7.3% |
| June 30, 2024 | $28.32M | +24.9% | -9.9% |
| March 31, 2024 | $31.44M | +56.2% | +17.1% |
| September 30, 2023 | $26.84M | — | +18.3% |
| June 30, 2023 | $22.68M | — | +12.7% |
- Metagenomi Therapeutics, Inc. showed a decrease of -13.5% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Metagenomi Therapeutics, Inc.’s r&d expense has grown by 0.0% (from $94.40 million to $94.43 million).
- The most recent figure is from Metagenomi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: